Rapport Therapeutics, Inc.
RAPP
$14.77
-$0.16-1.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 33.36% | 64.18% | 111.09% | 207.31% | 167.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.81% | 58.58% | 58.99% | 126.27% | 213.73% |
| Operating Income | -41.81% | -58.58% | -58.99% | -126.27% | -213.73% |
| Income Before Tax | -47.52% | -6.15% | -47.86% | -101.39% | -182.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -47.52% | -6.15% | -47.79% | -101.37% | -182.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.52% | -6.15% | -47.79% | -101.37% | -182.65% |
| EBIT | -41.81% | -58.58% | -58.99% | -126.27% | -213.73% |
| EBITDA | -42.02% | -58.56% | -57.80% | -124.52% | -211.58% |
| EPS Basic | 55.61% | 93.84% | 92.88% | 91.17% | 61.84% |
| Normalized Basic EPS | 55.60% | 90.86% | 92.83% | 91.16% | 61.83% |
| EPS Diluted | 55.61% | 93.84% | 92.88% | 91.17% | 61.84% |
| Normalized Diluted EPS | 55.60% | 90.86% | 92.83% | 91.16% | 61.83% |
| Average Basic Shares Outstanding | 232.30% | 1,622.93% | 1,976.21% | 2,179.36% | 640.68% |
| Average Diluted Shares Outstanding | 232.30% | 1,622.93% | 1,976.21% | 2,179.36% | 640.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |